Stryker Corporation $SYK Shares Sold by Royal London Asset Management Ltd.

Royal London Asset Management Ltd. reduced its stake in shares of Stryker Corporation (NYSE:SYK) by 1.1% during the 2nd quarter, Holdings Channel.com reports. The firm owned 340,466 shares of the medical technology company’s stock after selling 3,684 shares during the quarter. Royal London Asset Management Ltd.’s holdings in Stryker were worth $107,192,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of the company. Gables Capital Management Inc. acquired a new stake in Stryker in the 2nd quarter valued at $25,000. Kilter Group LLC acquired a new position in Stryker during the second quarter worth $25,000. Godfrey Financial Associates Inc. purchased a new position in Stryker during the fourth quarter valued at $26,000. Sankala Group LLC purchased a new position in Stryker during the fourth quarter valued at $26,000. Finally, Compass Financial Management LLC acquired a new stake in shares of Stryker in the second quarter valued at about $27,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Price Performance

NYSE:SYK opened at $331.32 on Friday. Stryker Corporation has a one year low of $281.00 and a one year high of $396.86. The stock has a market cap of $127.08 billion, a PE ratio of 34.33, a P/E/G ratio of 2.05 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The stock has a 50 day moving average price of $329.10 and a 200 day moving average price of $331.47.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The business had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. During the same period last year, the company earned $3.13 EPS. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities research analysts expect that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s dividend payout ratio (DPR) is currently 36.48%.

Analyst Ratings Changes

Several research firms recently weighed in on SYK. Piper Sandler reduced their price target on shares of Stryker from $420.00 to $390.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. Weiss Ratings reiterated a “hold (c)” rating on shares of Stryker in a report on Friday, July 31st. Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Leerink Partners cut their price objective on Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research note on Friday, June 5th. Finally, UBS Group assumed coverage on Stryker in a research report on Tuesday, July 28th. They set a “buy” rating and a $400.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $386.28.

Insider Activity

In other news, insider Debra King sold 826 shares of the company’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the transaction, the insider owned 6,210 shares of the company’s stock, valued at $2,088,423. This represents a 11.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 50,000 shares of the business’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the completion of the sale, the director owned 2,251,375 shares in the company, valued at approximately $765,692,637.50. This trade represents a 2.17% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 351,267 shares of company stock valued at $118,197,701. 4.60% of the stock is currently owned by company insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.